Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Sep 1;9(5):pkaf092.
doi: 10.1093/jncics/pkaf092.

Leveraging real-world evidence to personalize adjuvant therapy in HR+/HER2- early breast cancer

Yael Bar  1 , Steven J Isakoff  2 , Seth A Wander  2
Affiliations
Editorial

Leveraging real-world evidence to personalize adjuvant therapy in HR+/HER2- early breast cancer

Yael Bar et al. JNCI Cancer Spectr. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Y.B.: Consulting/Advisory Board: Eli Lilly, Novartis, Stemline/Menarini. Education/Speaking: Stemline/Menarini, Eli Lilly, Roche, Gilead, Pfizer, Novartis, AstraZeneca, MSD.

S.J.I.: Consulting/Advisory Board: Veracyte, Aktis. Institutional Research Support: Genentech, AstraZeneca, Merck, Marengo.

S.A.W.: Consulting/Advisory Board: Foundation Medicine, Veracyte, Hologic, Eli Lilly, Biovica, Pfizer/Arvinas, Puma Biotechnology, Novartis, AstraZeneca, Genentech, Regor Therapeutics, Stemline/Menarini, Gilead. Education/Speaking: Eli Lilly, Guardant Health, 2ndMD. Institutional Research Support: Genentech, Eli Lilly, Pfizer/Arvinas, Nuvation Bio, Regor Therapeutics, Sermonix, Puma Biotechnology, Stemline/Menarini, Phoenix Molecular Designs.

Y.B., S.J.I., and S.A.W. declare that their institutions are participating sites in the FLEX registry.

Comment on

  • MammaPrint predicts chemotherapy benefit in HR+HER2- early breast cancer: FLEX Registry real-world data.
    Brufsky AM, Hoskins KF, Conter HJ, Kelemen P, Habibi M, Samian L, Rahman RL, Lee L, Dias EC, Hampton R, Sieling BA, Osborne CR, Brown E, Elayoubi JA, Sharma P, Ramadurai J, Matt-Amaral L, Santillan AA, Davis S, Albaneze P, Ramaswamy H, Chmielewski-Stivers N, Menicucci A, Audeh W, Whitworth P, Johnson N, O'Shaughnessy J. Brufsky AM, et al. JNCI Cancer Spectr. 2025 Sep 1;9(5):pkaf079. doi: 10.1093/jncics/pkaf079. JNCI Cancer Spectr. 2025. PMID: 40796181 Free PMC article.

References

    1. Brufsky A, Hoskins K, Conter H, et al. MammaPrint predicts chemotherapy benefit in HR+HER2- early breast cancer: FLEX registry real-world data. JNCI Cancer Spectr. 2025;9:pkaf079. 10.1093/jncics/pkaf079 - DOI - PMC - PubMed
    1. Cardoso F, Van’t Veer LJ, Bogaerts J, et al. ; MINDACT Investigators. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375:717-729. 10.1056/NEJMoa1602253 - DOI - PubMed
    1. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 2001;19:980-991. 10.1200/JCO.2001.19.4.980 - DOI - PubMed
    1. Piccart M, van’t Veer LJ, Poncet C, et al. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol. 2021;22:476-488. 10.1016/S1470-2045(21)00007-3 - DOI - PubMed
    1. Kalinsky K, Barlow WE, Gralow JR, et al. 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385:2336-2347. 10.1056/NEJMoa2108873 - DOI - PMC - PubMed

LinkOut - more resources